Phase 2 findings on divesiran point to a potential way to control hematocrit while reducing repeated blood draws for those living with polycythemia vera, like Nona Baker.
News|Videos|January 3, 2019
A Calling to Help Patients With MPNs
Author(s)Lori Jemison, RN
For this MPN Hero, helping patients came naturally, she said.
Advertisement
For Lori Jemison, RN helping patients with myeloproliferative neoplasms (MPNs) came naturally.
Jemison, who was recently honored by CURE as an
Advertisement
Related to this article
Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.
Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.
Advertisement
Advertisement
Trending on CURE
1
5 Years of Leukemia Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
3 More Lung Cancer Breakthroughs From WCLC 2026
3
Blood Cancer Treatments in the FDA Pipeline: What Could Come Next
4
Oncology Nurse Leader Brings Stem Cell Transplant Care Closer to Home
5